Faculty Opinions recommendation of Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction.

Author(s):  
Samuel Heyman
2013 ◽  
Vol 84 (1) ◽  
pp. 192-197 ◽  
Author(s):  
Charles M. van Slambrouck ◽  
Fadi Salem ◽  
Shane M. Meehan ◽  
Anthony Chang

2018 ◽  
Vol 38 (2) ◽  
pp. 221-223
Author(s):  
Mónica Milla Castellanos ◽  
Eduardo Gutiérrez Martínez ◽  
Ángel Sevillano Prieto ◽  
Paola Rodríguez Ramos ◽  
Manuel Praga Terente

2019 ◽  
Vol 75 (2) ◽  
pp. 216-218
Author(s):  
Tanushri Mukherjee ◽  
Inam Danish Khan ◽  
Rena Guha ◽  
Tanmay Ganguly

2018 ◽  
Vol 8 (3) ◽  
pp. 207-215 ◽  
Author(s):  
Jose Torrealba ◽  
Nathan T. Sweed ◽  
Daniel Burguete ◽  
Allen R. Hendricks

Bile cast nephropathy (BCN) is seen in patients who have acute kidney injury and severe hyperbilirubinemia due to a wide range of hepatobiliary system diseases. Findings seen by renal biopsy include acute tubular injury with necrotic and sloughed epithelial cells, yellow-green pigment within tubular epithelial cells, and pigmented granular casts. Hall’s special stain for bile turns these casts green. In recent years, BCN has been described in a small number of case reports and clinical studies primarily in the setting of severe liver dysfunction. We present 2 diverse cases of BCN. The first involves an adult with hepatorenal syndrome secondary to alcoholic steatohepatitis and early cirrhosis. Second, we describe the first reported case of BCN in a child with fulminant hepatic failure due to Wilson’s disease. Our cases expand the spectrum of causative diseases, and they provide further evidence that BCN is a distinct pathologic entity which may be found in both adult and pediatric patients with a variety of severe liver diseases.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kevin Roedl ◽  
Dominik Jarczak ◽  
Andreas Drolz ◽  
Dominic Wichmann ◽  
Olaf Boenisch ◽  
...  

Abstract Background SARS-CoV-2 caused a pandemic and global threat for human health. Presence of liver injury was commonly reported in patients with coronavirus disease 2019 (COVID-19). However, reports on severe liver dysfunction (SLD) in critically ill with COVID-19 are lacking. We evaluated the occurrence, clinical characteristics and outcome of SLD in critically ill patients with COVID-19. Methods Clinical course and laboratory was analyzed from all patients with confirmed COVID-19 admitted to ICU of the university hospital. SLD was defined as: bilirubin ≥ 2 mg/dl or elevation of aminotransferase levels (> 20-fold ULN). Results 72 critically ill patients were identified, 22 (31%) patients developed SLD. Presenting characteristics including age, gender, comorbidities as well as clinical presentation regarding COVID-19 overlapped substantially in both groups. Patients with SLD had more severe respiratory failure (paO2/FiO2: 82 (58–114) vs. 117 (83–155); p < 0.05). Thus, required more frequently mechanical ventilation (95% vs. 64%; p < 0.01), rescue therapies (ECMO) (27% vs. 12%; p = 0.106), vasopressor (95% vs. 72%; p < 0.05) and renal replacement therapy (86% vs. 30%; p < 0.001). Severity of illness was significantly higher (SAPS II: 48 (39–52) vs. 40 (32–45); p < 0.01). Patients with SLD and without presented viremic during ICU stay in 68% and 34%, respectively (p = 0.002). Occurrence of SLD was independently associated with presence of viremia [OR 6.359; 95% CI 1.336–30.253; p < 0.05] and severity of illness (SAPS II) [OR 1.078; 95% CI 1.004–1.157; p < 0.05]. Mortality was high in patients with SLD compared to other patients (68% vs. 16%, p < 0.001). After adjustment for confounders, SLD was independently associated with mortality [HR3.347; 95% CI 1.401–7.999; p < 0.01]. Conclusion One-third of critically ill patients with COVID-19 suffer from SLD, which is associated with high mortality. Occurrence of viremia and severity of illness seem to contribute to occurrence of SLD and underline the multifactorial cause.


2018 ◽  
Vol 18 ◽  
pp. S291-S292
Author(s):  
Tamer Khashab ◽  
Ashley Manganiello ◽  
Julianne Hibbs ◽  
Thomas Oliver ◽  
Jonathan Doroshow ◽  
...  

2010 ◽  
Vol 52 (2) ◽  
pp. e105-e107 ◽  
Author(s):  
Akitoshi Murayama ◽  
Daiki Abukawa ◽  
Keiko Watanabe ◽  
Hiroaki Umebayashi ◽  
Tetsuji Inagaki ◽  
...  

1999 ◽  
Vol 38 (7) ◽  
pp. 575-579 ◽  
Author(s):  
Sachiyo FURUTA ◽  
Yukako OZAWA ◽  
Kiyoshi MAEJIMA ◽  
Hirokazu TASHIRO ◽  
Tetsuji KITAHORA ◽  
...  

2019 ◽  
Vol 15 (1) ◽  
pp. 99-112 ◽  
Author(s):  
Mariusz Piechota ◽  
Anna Piechota ◽  
Małgorzata Misztal ◽  
Szymon Bernas ◽  
Iwona Pietraszek-Grzywaczewska

Sign in / Sign up

Export Citation Format

Share Document